Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Core Viewpoint - Biodesix, Inc. will release its financial results for Q4 and the full year of 2025 on February 26, 2026, followed by a conference call to discuss these results and provide a business update [1]. Company Overview - Biodesix is a leading diagnostic solutions company focused on improving clinical care and outcomes for patients, particularly in lung disease [3]. - The company offers diagnostic tests such as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, which aid in clinical decision-making [3]. - Biodesix Development Services support biopharmaceutical and life sciences institutions in developing diagnostic tests and therapeutics [3].